The DOI matches its Crossref record, with a small difference in title or year; 195 of the 196 references it cites were found in a registry or an index.
Omics and Drug Response
Abstract
A new generation of technologies commonly named omics permits assessment of the entirety of the components of biological systems and produces an explosion of data and a major shift in our concepts of disease. These technologies will likely shape the future of health care. One aspect of these advances is that the data generated document the uniqueness of each human being in regard to disease risk and treatment response. These developments have reemphasized the concept of personalized medicine. Here we review the impact of omics technologies on one key aspect of personalized medicine: the individual drug response. We describe how knowledge of different omics may affect treatment decisions, namely drug choice and drug dose, and how it can be used to improve clinical outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of particular clinical relevance, CYP3A4 is responsible for metabolizing nearly 50% of commonly prescribed medications (65, 66).”
From Case Report: Integrating clinical presentation and genetic analysis in P450 oxidoreductase deficiency: a novel mutation and systematic review (2026) · cites this paper as [65]
Citations
Cites
1 retracted
Antoine, D. J., Jenkins, R. E., Dear, J. W., Williams, D. P., McGill, M. R., Sharpe, M. R., Craig, D. G. N., Simpson, K. J., Jaeschke, H., & Park, B. K. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.019 · Cited by 307
RetractedRNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771
Alternative isoform regulation in human tissue transcriptomes
Wang, E. T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, S. F., Schroth, G. P., & Burge, C. B. (2008) · Nature · doi:10.1038/nature07509 · Cited by 5,181
Research works printed but not linked: 6
- Natl. Res. Counc., 2011, Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease
- Rappaport SM, 2011, Nucleic Acids Res., 21, 5
- 10.1038/nature10166 · DOI · Paper page
- Zhang W, 2010, Curr. Opin. Mol. Ther., 12, 695
- Rhea JM, 2011, MLO Med. Lab. Obs., 43, 10
- Blay J-Y, 2011, Semin. Oncol., 38, S3
Cited by
Sorted by citations
Analytical Methods in Untargeted Metabolomics: State of the Art in 2015
Alonso, A., Marsal, S., & Julià, A. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00023 · Cited by 727
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars
Li, M., Tian, S., Jin, L. G., Zhou, G., Li, Y., Zhang, Y., Wang, T., Yeung, C. K. L., Chen, L., Ma, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2811 · Cited by 560
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z. M., Zhou, J., & Chen, S. (2016) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 415
Worst, B. C., van Tilburg, C. M., Balasubramanian, G. P., Fiesel, P., Witt, R., Freitag, A., Boudalil, M., Previti, C., Wolf, S., Schmidt, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.009 · Cited by 338
Self-citationWolking, S., Schaeffeler, E., Lerche, H., Schwab, M. G., & Nies, A. T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0267-1 · Cited by 313
Self-citationKyobula, M., Aremu, A., Alexander, M. R., Saleh, E., Wildman, R. D., Ashcroft, I., Gellert, P. R., & Roberts, C. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.06.025 · Cited by 290
Deep learning for drug response prediction in cancer
Baptista, D., Ferreira, P. G., & Rocha, M. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz171 · Cited by 243
Murphy, E., Murtagh, F. E., Carey, I., & Sheerin, N. (2008) · Nephron Clinical Practice · doi:10.1159/000183177 · Cited by 190
Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network
Bush, W. S., Crosslin, D., Obeng, A. O., Wallace, J., Almoguera, B., Basford, M., Bielinski, S. J., Carrell, D., Connolly, J. J., Crawford, D. C., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.350 · Cited by 184
Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions
Pirmohamed, M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090413-025419 · Cited by 174
Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects
Riedmaier, A. E., Fisel, P., Nies, A. T., Schaeffeler, E., & Schwab, M. G. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.11.005 · Cited by 161
Self-citationImmune checkpoint inhibitor combinations: Current efforts and important aspects for success
Kon, E., & Benhar, I. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.07.004 · Cited by 121
Teng, M., Zhu, W., Wang, D., Qi, S., Wang, Y., Yan, J., Dong, K., Zheng, M., & Wang, C. (2017) · Aquatic Toxicology · doi:10.1016/j.aquatox.2017.11.009 · Cited by 117
Zobel‐Roos, S., Schmidt, A., Mestmäcker, F., Mouellef, M., Huter, M., Uhlenbrock, L., Kornecki, M., Lohmann, L., Ditz, R., & Strube, J. (2019) · Processes · doi:10.3390/pr7020094 · Cited by 87
Pharmacogenomics of human P450 oxidoreductase
Pandey, A. V., & Sproll, P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00103 · Cited by 92
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
Neul, C., Schaeffeler, E., Sparreboom, A., Laufer, S., Schwab, M. G., & Nies, A. T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.08.003 · Cited by 93
Self-citationWilk–Zasadna, I., Bernasconi, C., Pelkonen, O., & Coecke, S. (2014) · Toxicology · doi:10.1016/j.tox.2014.10.006 · Cited by 94
Li, J., Lei, K., Wu, Z., Li, W., Liu, G., Liu, J., Cheng, F., & Tang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10052 · Cited by 87
P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms
Burkhard, F. Z., Parween, S., Udhane, S. S., Flück, C. E., & Pandey, A. V. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.003 · Cited by 79
Fisel, P., Schaeffeler, E., & Schwab, M. G. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.343 · Cited by 74
Self-citationDevelopment of Human Membrane Transporters: Drug Disposition and Pharmacogenetics
Mooij, M. G., Nies, A. T., Knibbe, C. A. J., Schaeffeler, E., Tibboel, D., Schwab, M. G., & de Wildt, S. N. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0328-5 · Cited by 72
Self-citationMato, E. P. M., Guewo‐Fokeng, M., Essop, M. F., & Owira, P. M. O. (2018) · Medicine · doi:10.1097/md.0000000000011349 · Cited by 76
Genomics and transcriptomics in drug discovery
Dopazo, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.003 · Cited by 69
Advance computational tools for multiomics data learning
Mansoor, S., Hamid, S., Tuan, T. T., Park, J.-E., & Chung, Y. S. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108447 · Cited by 60
Digital Twins in Biomanufacturing
Zobel‐Roos, S., Schmidt, A., Uhlenbrock, L., Ditz, R., Köster, D., & Strube, J. (2020) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2020_146 · Cited by 59
Brown, R. W., Chadwick, D. R., Zang, H., & Jones, D. L. (2021) · Soil Biology and Biochemistry · doi:10.1016/j.soilbio.2021.108351 · Cited by 58
Yang, B., Jin, C., Liu, Y., Yu, W., & Kang, H. (2014) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2014.939321 · Cited by 56
Celecoxib-Induced Self-Assembly of Smart Albumin-Doxorubicin Conjugate for Enhanced Cancer Therapy
Shi, L., Xu, L., Wu, C., Bai, X., Jin, X., Yang, J., & Zhu, X. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b00875 · Cited by 49
Zhang, Y., Zhang, Z., Zhao, Y., Cheng, S., & Ren, H. (2013) · Environmental Science & Technology · doi:10.1021/es3048976 · Cited by 46
Higgins, G. A., Allyn-Feuer, A., Barbour, E., & Athey, B. D. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.106 · Cited by 46
Effect of short-chain chlorinated paraffins on metabolic profiling of male SD rats
Geng, N., Luo, Y., Cao, R., Song, X., Li, F., Wang, F., Gong, Y., Xing, L., Zhang, H., & Chen, J. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.141404 · Cited by 43
Personalized laboratory medicine: a patient-centered future approach
Žitnik, I. P., Černe, D., Mancini, I., Simi, L., Pazzagli, M., Resta, C. D., Podgornik, H., Lampret, B. R., Podkrajšek, K. T., Sipeky, C., et al. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0181 · Cited by 42
Self-citationGenome-wide sequence analyses of ethnic populations across Russia
Zhernakova, D. V., Brukhin, V. B., Malov, S. V., Oleksyk, T. K., Koepfli, K., Zhuk, A. S., Dobrynin, P. V., Kliver, S. F., Cherkasov, N., Tamazian, G., et al. (2019) · Genomics · doi:10.1016/j.ygeno.2019.03.007 · Cited by 40
Pharmacogenetics of Drugs Used in the Treatment of Cancers
Franczyk, B., Rysz, J., & Gluba-Brzózka, A. (2022) · Genes · doi:10.3390/genes13020311 · Cited by 46
Pharmacogenomics: a key component of personalized therapy
Schwab, M. G., & Schaeffeler, E. (2012) · Genome Medicine · doi:10.1186/gm394 · Cited by 41
Self-citationShen, Y., Tong, M., Liang, Q., Guo, Y., Sun, H. Q., Zheng, W., Ao, L., Guo, Z., & She, F. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.91 · Cited by 40
Stegemann, S. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.11.003 · Cited by 39
Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’
Ho, M., McCann, A. H., Bianchi, G., Zhang, L., Dowling, P., Bazou, D., O’Gorman, P., & Anderson, K. C. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1337115 · Cited by 38
Genetic findings in sport-related concussions: potential for individualized medicine?
McDevitt, J. K., & Krynetskiy, E. Y. (2017) · Concussion · doi:10.2217/cnc-2016-0020 · Cited by 37
Applications of chromatographic methods in metabolomics: A review
Ovbude, S. T., Sharmeen, S., Kyei, I., Olupathage, H., Jones, J. F., Bell, R. J., Powers, R., & Hage, D. S. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124124 · Cited by 44
A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Kwatra, M. M. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009616666161227091522 · Cited by 37
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics
Tworowski, D., Gorohovski, A., Mukherjee, S., Carmi, G., Levy, E., Detroja, R., Mukherjee, S. B., & Frenkel‐Morgenstern, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa969 · Cited by 35
Stimpfle, F., Karathanos, A., Droppa, M., Metzger, J. C., Rath, D., Müller, K., Tavlaki, E., Schäffeler, E., Winter, S., Schwab, M. G., et al. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.006 · Cited by 32
Self-citationJiang, J., Zhang, C., Wang, L., Wang, X., He, H., Wu, S., & Zhao, X. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.154687 · Cited by 32
Riedmaier, A. E., Schaeffeler, E., Nies, A. T., Mörike, K., & Schwab, M. G. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12330 · Cited by 33
Self-citationZhang, C., Hong, H., Mendrick, D. L., Tang, Y., & Cheng, F. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.81 · Cited by 32
Genetic variation of platelet function and pharmacology: An update of current knowledge
Schaeffeler, E., Schaeffeler, E., Gawaz, M., Schwab, M. G., & Geisler, T. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0145 · Cited by 31
Self-citationBridging Genomics and Phenomics
Chen, D., Chen, M., Altmann, T., & Klukas, C. (2013) · Springer eBooks · doi:10.1007/978-3-642-41281-3_11 · Cited by 31
Counteracting antibiotic resistance: breaking barriers among antibacterial strategies
Baquero, F., Coque, T. M., & Cantón, R. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.925881 · Cited by 28
Parween, S., Fernández‐Cancio, M., Benito‐Sanz, S., Camats, N., Velazquez, M. N. R., López‐Siguero, J., Udhane, S. S., Kagawa, N., Flück, C. E., Audı́, L., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa076 · Cited by 27
Stieger, B., Mahdi, Z., & Jäger, W. R. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105010 · Cited by 28
Blattmann, P., Henriques, D., Zimmermann, M., Frommelt, F., Sauer, U., Saez-Rodriguez, J., & Aebersold, R. (2017) · Cell Systems · doi:10.1016/j.cels.2017.11.002 · Cited by 26
Histology and metabonomics reveal the toxic effects of kresoxim-methyl on adult zebrafish
Fang, N., Zhang, C., Hu, H., Li, Y., Wang, X., Zhao, X., & Jiang, J. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.136739 · Cited by 27
Personalized Biochemistry and Biophysics
Kroncke, B. M., Vanoye, C. G., Meiler, J., George, A. L., & Sanders, C. R. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00189 · Cited by 27
ABCB1 genetic variants in leukemias: current insights into treatment outcomes
Ankathil, R. (2017) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s105208 · Cited by 27
Petersen, K. E., Prows, C. A., Martin, L. J., & Maglo, K. N. (2014) · Public Health Genomics · doi:10.1159/000362359 · Cited by 26
Genetic Biomarkers in Epilepsy
Weber, Y. G., Nies, A. T., Schwab, M. G., & Lerche, H. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0262-5 · Cited by 27
Self-citationVelazquez, M. N. R., Parween, S., Udhane, S. S., & Pandey, A. V. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.127 · Cited by 26
Simeon, V., Todoerti, K., Rocca, F. L., Caivano, A., Trino, S., Lionetti, M., Agnelli, L., Luca, L. D., Laurenzana, I., Neri, A., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817514 · Cited by 25
Parween, S., Velazquez, M. N. R., Udhane, S. S., Kagawa, N., & Pandey, A. V. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01187 · Cited by 24
Li, Y., Zhang, Q., Yu, Y., Li, X., & Tan, H. (2020) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2020.10.033 · Cited by 25
European Healthcare Systems Readiness to Shift from ‘One-Size Fits All’ to Personalized Medicine
Halfmann, S. S. G., Evangelatos, N. G., Schröder‐Bäck, P., & Brand, A. M. (2016) · Personalized Medicine · doi:10.2217/pme-2016-0061 · Cited by 24
Epigenomic Mapping and Effect Sizes of Noncoding Variants Associated with Psychotropic Drug Response
Higgins, G. A., Allyn-Feuer, A., & Athey, B. D. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.105 · Cited by 23
Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice
Spanakis, M., Patelarou, A. E., & Patelarou, E. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030056 · Cited by 23
Systems Approaches in Risk Assessment
Lesko, L. J., Zheng, S., & Schmidt, S. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.29 · Cited by 23
Novák, M., Boleslavská, T., Grof, Z., Waněk, A., Zadražil, A., Beránek, J., Kovačík, P., & Štĕpánek, F. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1176-z · Cited by 22
Beyond drugs: the evolution of genes involved in human response to medications
Fuselli, S. (2019) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2019.1716 · Cited by 22
Establishing Serum Reference Ranges for Antihypertensive Drugs
Rognstad, S., Søraas, C. L., Bergland, O. U., Høieggen, A., Strømmen, M., Helland, A., & Opdal, M. S. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000806 · Cited by 23
Khalaj, Z., Baratieh, Z., Nikpour, P., Schwab, M. G., Schaeffeler, E., Mokarian, F., Khanahmad, H., Salehi, R., Mürdter, T. E., & Salehi, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00530 · Cited by 21
Self-citationApplications of omics and nanotechnology to improve pig embryo production in vitro
Lucas, C. G., Chen, P. R., Seixas, F. K., Prather, R. S., & Collares, T. V. (2019) · Molecular Reproduction and Development · doi:10.1002/mrd.23260 · Cited by 21
Chen, L., Luo, Y., Zhang, C., Liu, X., Fang, N., Wang, X., Zhao, X., & Jiang, J. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.140747 · Cited by 21
Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy
Staiger, H., Schaeffeler, E., Schwab, M. G., & Häring, H. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.363 · Cited by 20
Self-citationDimitrakopoulou, K., Dimitrakopoulos, G. Ν., Sgarbas, K., & Bezerianos, A. (2013) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2013.0055 · Cited by 20
Malentacchi, F., Mancini, I., Brandslund, I., Vermeersch, P., Schwab, M. G., Marc, J., van Schaik, R. H. N., Siest, G., Theodorsson, E., Pazzagli, M., et al. (2015) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmdi-2015-0012 · Cited by 20
Self-citationClinical Translation in the Virtual Liver Network
Kuepfer, L., Kerb, R., & HENNEY, A. M. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.25 · Cited by 20
Khatami, F., Mohajeri‐Tehrani, M. R., & Tavangar, S. M. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190228102212 · Cited by 19
Dickens, A. M., Larkin, J. R., Davis, B. G., Griffin, J. L., Claridge, T. D. W., Sibson, N. R., & Anthony, D. C. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9622-0 · Cited by 19
Personalized medicine into the next generation
Ingelman‐Sundberg, M. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12325 · Cited by 19
Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk
Justenhoven, C. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00258 · Cited by 18
Doble, B., Harris, A., Thomas, D. M., Fox, S. B., & Lorgelly, P. K. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.142 · Cited by 18
Multidrug Resistance Proteins of the ABCC Subfamily
Nies, A. T., & Lang, T. (2014) · doi:10.1002/9781118705308.ch10 · Cited by 18
Achieving the World Health Organization's vision for clinical pharmacology
Martin, J. H., Henry, D. A., Gray, J., Day, R. O., Bochner, F., Ferro, A., Pirmohamed, M., Mörike, K., & Schwab, M. G. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12803 · Cited by 17
Self-citationTremmel, R., Klein, K., Battke, F., Fehr, S., Winter, S., Scheurenbrand, T., Schaeffeler, E., Biskup, S., Schwab, M. G., & Zanger, U. M. (2019) · Human Genetics · doi:10.1007/s00439-019-02093-7 · Cited by 17
Self-citationDai, Y., Wu, D., Carroll, I. M., Zou, F., & Zou, B. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf266 · Cited by 20
MLG2Net: Molecular Global Graph Network for Drug Response Prediction in Lung Cancer Cell Lines
Tran, T.-O., Nguyen, T.-H., Nguyen, T. T., & Le, N. Q. K. (2025) · Journal of Medical Systems · doi:10.1007/s10916-025-02182-3 · Cited by 15
‘Omics’: an emerging field in pain research and management
Gazerani, P., & Vinterhøj, H. S. H. (2016) · Future Neurology · doi:10.2217/fnl-2016-0018 · Cited by 15
Pharmacometrics and systems pharmacology for metabolic bone diseases
Riggs, M. M., & Cremers, S. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13881 · Cited by 15
The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7
Precht, J. C., Schroth, W., Klein, K., Brauch, H. B., Krynetskiy, E. Y., Schwab, M. G., & Mürdter, T. E. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.053405 · Cited by 14
Self-citationAboul‐Soud, M. A. M., Al-Zahrani, A., & Mahmoud, A. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.10.052 · Cited by 14
Genetic and Epigenetic Regulation of Organic Cation Transporters.
Kölz, C., Schaeffeler, E., Schwab, M., & Nies, A. (2021) · Handbook of Experimental Pharmacology · doi:10.1007/164_2021_450 · Cited by 14
Self-citationEvolutionary Diagnosis of non-synonymous variants involved in differential drug response
Gerek, Z. N., Liu, L., Gerold, K., Biparva, P., Thomas, E. D., & Kumar, S. (2015) · BMC Medical Genomics · doi:10.1186/1755-8794-8-s1-s6 · Cited by 13
Applying genomics in heart transplantation
Keating, B. J., Pereira, A. C., Snyder, M. P., & Piening, B. (2018) · Transplant International · doi:10.1111/tri.13119 · Cited by 12
Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development
Kandel, S. E., Wienkers, L. C., & Lampe, J. N. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00022-5 · Cited by 12
Pharmacogenovigilance: A Pharmacogenomics Pharmacovigilance Program
Awada, Z., & Zgheib, N. K. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.44 · Cited by 11
Alazzo, A., Alnatour, M., Spriggs, K. A., Stolnik, S., Ghaemmaghami, A. M., Kim, D., & Alexander, C. (2019) · Molecular Omics · doi:10.1039/c8mo00139a · Cited by 10
Effects of SLCO1B1 Genetic Variant on Metabolite Profile in Participants on Simvastatin Treatment
Silva, L. F., Ravi, R., Vangipurapu, J., Oravilahti, A., & Laakso, M. (2022) · Metabolites · doi:10.3390/metabo12121159 · Cited by 10
Arlanov, R., Lang, T., Jedlitschky, G., Schaeffeler, E., Ishikawa, T., Schwab, M. G., & Nies, A. T. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.27 · Cited by 9
Self-citationHow paediatric drug development and use could benefit from OMICs: A c4c expert group white paper
Neumann, E., Schreeck, F., Herberg, J. A., Jacqz-Aigrain, É., der Zee, A. H. M., Pérez‐Martínez, A., Hawcutt, D. B., Schaeffeler, E., Rane, A., de Wildt, S. N., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15216 · Cited by 9
Self-citationCorbally, M.-K., & Regan, J. C. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.1016962 · Cited by 8
The Significance of Transcriptome Sequencing in Personalized Cancer Medicine
Zhang, S., Wei, J. S., & Khan, J. I. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396967-5.00004-9 · Cited by 9
Metadata
- Authors
- Meyer, U. A., Zanger, U. M., & Schwab, M.
- Affiliations
- University of Basel (CH)
- Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (DE)
- Universitätsklinikum Tübingen (DE)
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2013-01-06
- Volume
- 53
- Issue
- 1
- Pages
- 475-502
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2098156682
- Cited by
- 157
- References
- 196
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 6 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 12 · 2019: 17 · 2018: 10 · 2017: 15 · 2016: 12 · 2015: 17 · 2014: 17 · 2013: 14
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Robert Bosch Stiftung
- Bundesministerium für Bildung und Forschung
- National Institutes of Health
- National Human Genome Research Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- omics technologies, drug response, personalized medicine, pharmacogenomics, drug selection, drug dosing, treatment response variability, clinical outcomes, precision medicine
- MeSH terms
- Animals, Humans, Pharmacogenetics, Genomics, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
